Literature DB >> 15579430

Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.

Gianni Gerlini1, Adrian Tun-Kyi, Christa Dudli, Günter Burg, Nicola Pimpinelli, Frank O Nestle.   

Abstract

CD1 molecules are expressed by antigen-presenting cells such as dendritic cells and mediate primary immune responses to lipids and glycolipids which have been shown to be expressed by various tumors. Glycolipids are expressed by melanoma cells but, despite their immunogenicity, no efficient spontaneous immune responses are elicited. As IL-10 has previously been shown to down-regulate CD1a on dendritic cells and is known to be expressed by various melanoma cell lines, we investigated if melanoma-derived IL-10 could down-regulate CD1 molecule expression on dendritic cells as a possible way to circumvent immune recognition. We found that CD1a, CD1b, CD1c, and CD1d were significantly down-regulated on dendritic cells in metastatic (n = 10) but not in primary melanoma lesions (n = 10). We further detected significantly higher IL-10 protein levels in metastatic than in primary melanomas. Moreover, supernatants from metastatic melanomas were significantly more effective in down-regulating CD1 molecules on dendritic cells than supernatants from primary melanoma cultures. This effect was blocked using a neutralizing IL-10 antibody in a dose dependent manner. Our findings suggest that metastatic but not primary melanomas can down-regulate CD1 molecules on infiltrating dendritic cells by secreting IL-10 which may represent a novel way to escape the immune response directed against the tumor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579430      PMCID: PMC1618726          DOI: 10.1016/S0002-9440(10)63238-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  70 in total

1.  Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells.

Authors:  B Fernandez Pujol; F C Lucibello; M Zuzarte; P Lütjens; R Müller; K Havemann
Journal:  Eur J Cell Biol       Date:  2001-01       Impact factor: 4.492

2.  Bacillus Calmette-Guerin down-regulates CD1b induction by granulocyte-macrophage colony stimulating factor in human peripheral blood monocytes.

Authors:  S P Prete; A Giuliani; E Iona; L Fattorini; G Orefici; O Franzese; E Bonmassar; G Graziani
Journal:  J Chemother       Date:  2001-02       Impact factor: 1.714

3.  Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.

Authors:  J M Kirkwood; R A Mascari; H D Edington; M S Rabkin; R S Day; T L Whiteside; D R Vlock; J M Shipe-Spotloe
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

4.  IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis.

Authors:  D Förtsch; M Röllinghoff; S Stenger
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

Authors:  R D Brown; B Pope; A Murray; W Esdale; D M Sze; J Gibson; P J Ho; D Hart; D Joshua
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

6.  Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.

Authors:  G V Shurin; M R Shurin; S Bykovskaia; J Shogan; M T Lotze; E M Barksdale
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

7.  Regulatory activity of autocrine IL-10 on dendritic cell functions.

Authors:  S Corinti; C Albanesi; A la Sala; S Pastore; G Girolomoni
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

8.  Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells.

Authors:  G Gerlini; H P Hefti; M Kleinhans; B J Nickoloff; G Burg; F O Nestle
Journal:  J Invest Dermatol       Date:  2001-09       Impact factor: 8.551

9.  Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

Authors:  B Almand; J I Clark; E Nikitina; J van Beynen; N R English; S C Knight; D P Carbone; D I Gabrilovich
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

10.  Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.

Authors:  J Nemunaitis; T Fong; P Shabe; D Martineau; D Ando
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

View more
  49 in total

1.  Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.

Authors:  Asa Andersson; Minu K Srivastava; Marni Harris-White; Min Huang; Li Zhu; David Elashoff; Robert M Strieter; Steven M Dubinett; Sherven Sharma
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 2.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 3.  Dietary agents in cancer prevention: an immunological perspective.

Authors:  Ya Ying Zheng; Bharathi Viswanathan; Pravin Kesarwani; Shikhar Mehrotra
Journal:  Photochem Photobiol       Date:  2012-03-30       Impact factor: 3.421

Review 4.  Regulatory T cells: present facts and future hopes.

Authors:  Christian Becker; Sabine Stoll; Tobias Bopp; Edgar Schmitt; Helmut Jonuleit
Journal:  Med Microbiol Immunol       Date:  2006-05-20       Impact factor: 3.402

5.  Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape.

Authors:  Sanmay Bandyopadhyay; Thomas J Quinn; Lisa Scandiuzzi; Indranil Basu; Ari Partanen; Wolfgang A Tomé; Fernando Macian; Chandan Guha
Journal:  J Immunol       Date:  2016-01-11       Impact factor: 5.422

6.  Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy.

Authors:  Gianni Gerlini; Serena Sestini; Paola Di Gennaro; Carmelo Urso; Nicola Pimpinelli; Lorenzo Borgognoni
Journal:  Clin Exp Metastasis       Date:  2012-06-27       Impact factor: 5.150

7.  Identification of a novel population of highly cytotoxic c-Met-expressing CD8+ T lymphocytes.

Authors:  Mahdia Benkhoucha; Nicolas Molnarfi; Gürkan Kaya; Elodie Belnoue; Kristbjörg Bjarnadóttir; Pierre-Yves Dietrich; Paul R Walker; Denis Martinvalet; Madiha Derouazi; Patrice H Lalive
Journal:  EMBO Rep       Date:  2017-07-27       Impact factor: 8.807

8.  CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy.

Authors:  P Di Gennaro; G Gerlini; C Urso; S Sestini; P Brandani; N Pimpinelli; L Borgognoni
Journal:  Clin Exp Metastasis       Date:  2016-07-30       Impact factor: 5.150

9.  Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.

Authors:  Mariana Rodríguez Zubieta; David Furman; Marcela Barrio; Alicia Inés Bravo; Enzo Domenichini; José Mordoh
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 10.  Advances and challenges: dendritic cell vaccination strategies for glioblastoma.

Authors:  Teilo H Schaller; John H Sampson
Journal:  Expert Rev Vaccines       Date:  2016-08-10       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.